Quarterly report pursuant to Section 13 or 15(d)

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

v3.7.0.1
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
3 Months Ended 6 Months Ended
Mar. 31, 2017
Mar. 31, 2016
Mar. 31, 2017
Mar. 31, 2016
REVENUES        
Neurometric Services $ 31,900 $ 20,700 $ 54,100 $ 45,400
OPERATING EXPENSES        
Cost of neurometric services revenue 3,800 1,400 7,600 2,700
Research 29,300 22,700 60,900 45,300
Product development 292,800 183,000 588,100 306,400
Sales and marketing 191,800 133,000 297,500 256,100
General and administrative 934,200 370,600 1,955,900 749,600
Total operating expenses 1,451,900 710,700 2,910,000 1,360,100
OPERATING LOSS (1,420,000) (690,000) (2,855,900) (1,314,700)
OTHER INCOME (EXPENSE):        
Interest expense, net (1,400) (239,600) (3,900) (739,800)
Loss on extinguishment of debt (2,337,400)
Gain on derivative liabilities 786,900 798,200
Total other income (expense) (1,400) 547,300 (3,900) (2,279,000)
LOSS BEFORE PROVISION FOR INCOME TAXES (1,421,400) (142,700) (2,859,800) (3,593,700)
Provision for income taxes 30,600 32,400 300
NET LOSS $ (1,452,000) $ (142,700) $ (2,892,200) $ (3,594,000)
BASIC AND DILUTED LOSS PER SHARE:        
From continuing operations (in dollars per share) $ (0.61) $ (0.28) $ (1.29) $ (7.01)
WEIGHTED AVERAGE SHARES OUTSTANDING:        
Basic and Diluted (in shares) 2,372,394 513,345 2,236,728 512,716